ArticleJournal of medical case reports2025
Primary adenosquamous carcinoma of the prostate with rapid elevation of prostate-specific antigen: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary adenosquamous carcinoma of the prostate is an extremely rare and aggressive variant, accounting for less than 1% of all prostate cancers. Due to its rarity, the prognosis is poor, with no established treatment. Prostate-specific antigen levels are typically within the normal range in primary adenosquamous carcinoma of the prostate. CASE PRESENTATION: We present the case of a 57-year-old East Asian male in whom pathological and imaging findings led to the diagnosis of primary adenosquamous carcinoma of the prostate. His prostate-specific antigen levels were initially high and continued to increase rapidly thereafter to 161.89 ng/ml. Although hormonal therapy achieved a reduction in prostate-specific antigen levels, the disease progressed rapidly, with extensive metastases to multiple sites, including the lung, lymph nodes, pancreas, bone, and skeletal muscle as an extremely rare metastatic site. The patient died 6 months after diagnosis despite subsequent multidisciplinary treatment.
conclusionThis patient with primary adenosquamous carcinoma of the prostate demonstrated rapid increase of prostate-specific antigen as an uncommon clinical feature. Further accumulation of cases is needed to understand and treat this rare and aggressive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.